A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00943826
First received: July 17, 2009
Last updated: September 6, 2013
Last verified: September 2013
  Purpose

This 2 arm study investigated the efficacy and safety of the addition of bevacizumab (Avastin®) to the current standard of care (multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide) as compared to the current standard of care alone. Patients were randomly assigned to either the Avastin® (10 mg/kg iv q2w) or the placebo arm, in combination with radiation therapy (total dose 60 Gy, administered as 2 Gy fractions, 5 days/week)plus temozolomide (75 mg/m2 po daily) for 6 weeks. After a 4 week treatment break, patients continued to receive Avastin® (10 mg/kg iv q2w) or placebo, plus temozolomide (150-200 mg/m2 po daily on days 1-5 of each 4 week cycle) for 6 cycles of maintenance treatment. Following the maintenance phase, Avastin® (15 mg/kg iv q3w) or placebo monotherapy was continued. The anticipated time on study treatment was until disease progression/unacceptable toxicity.


Condition Intervention Phase
Glioblastoma
Drug: bevacizumab [Avastin®]
Drug: Placebo
Drug: temozolomide
Radiation: Radiation therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Co-Primary: Progression-free Survival (PFS) as Assessed by Investigator [ Time Frame: Randomization until Progressive Free Survival Event [Until data cutoff= 31 March 2012 (up to 34 months)] ] [ Designated as safety issue: No ]

    PFS was defined as the time from randomization to disease progression or death due to any cause.

    Disease progression (PD) was assessed by the investigator using adapted Macdonald response criteria (modified World Health Organization (WHO) criteria) based on 3 components: radiological tumor assessments using Magnetic Resonance Imaging (MRI) scans, neurological assessment and changes in corticosteroid use.

    PD was determined as ≥ 25% increase in the sum of the products of the perpendicular longest diameters of all index lesions (enhancing, measurable) compared with the smallest recorded sum (nadir) during the study or unequivocal progression of existing non-index lesions (non-enhancing and enhancing, non-measurable) or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) with no need for a confirmatory scan.

    Data from the final analysis is presented.


  • Co-Primary: Overall Survival (OS) [ Time Frame: Randomization until Overall Survival Event ] [ Designated as safety issue: No ]
    Overall Survival was defined as the time from randomization to death due to any cause.


Secondary Outcome Measures:
  • Progression-free Survival (PFS) as Assessed by an Independent Review Facility [ Time Frame: Randomization until Progressive Free Survival Event [Until data cutoff= 31 March 2012 (up to 34 months)] ] [ Designated as safety issue: No ]
    An Independent Review Facility reviewed the magnetic resonance imaging (MRI) scans used by the investigator to evaluate radiological tumor response. PFS was defined as the time from randomization to disease progression or death due to any cause.

  • Percentage of Participants With One-Year Survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Percentage of participants who are still alive 1 year post randomization.

  • Percentage of Participants With Two-year Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Percentage of participants who are still alive 2 years post randomization.

  • Duration of Stable/Improved Health Related Quality of Life (HRQoL) Using the European Organisation for Research and Treatment of Cancer Scales (EORTC) QLQ-C30 and BN20 [ Time Frame: Randomization until Progressive Free Survival Event [Until data cutoff= 31 March 2012 (up to 34 months)] ] [ Designated as safety issue: No ]
    Stable and Improved HRQoL during PFS time was determined using the EORTC QLQ-C30 and BN20 questionnaires. The EORTC QLQ-C30 is a 30-item self-reported questionnaire in 5 functional scales (physical,role,emotional,cognitive,social), 3 symptoms scales, 6 single-item measures and a global health status/QoL scale.Patients rated the items on a 4-point scale: 1=not at all to 4=very much.Global health status/QoL items were rated on a 7-point scale: 1=very poor to 7=excellent. The BN20 consisted of 20 questions in 4 scales(future uncertainty,visual disorder,motor dysfunction,communication deficit) and 7 single-item measures rated on a 4-point scale: 1=not at all to 4=very much. A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100. Stable HRQoL was defined as a change from baseline within 10 points.Improved HRQoL is defined as an increase of at least 10 points for functioning/global health status and a decrease of at least 10 points for symptoms.

  • Number of Participants With Adverse Events, Serious Adverse Events and Death [ Time Frame: Until data cutoff= 31 March 2012 (up to 34 months) ] [ Designated as safety issue: No ]

    An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.

    A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.



Enrollment: 921
Study Start Date: June 2009
Estimated Study Completion Date: April 2014
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bevacizumab + RT+Temozolomide
In the Concurrent Phase participants received radiotherapy (RT) in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and bevacizumab 10 mg/kg intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity.
Drug: bevacizumab [Avastin®]
10 mg/kg intravenously every 2 weeks in the Concurrent and Maintenance Phases. 15 mg/kg intravenously every 3 weeks in the Monotherapy Phase.
Drug: temozolomide
75 mg/m2 once daily for 6 weeks, followed by 150-200 mg/m2 once daily on days 1-5 of each 6 x 4 week cycle.
Radiation: Radiation therapy
30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks
Placebo Comparator: Placebo + RT+ Temozolomide
In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 week and temozolomide 75 mg/m^2 daily for a maximum of 49 days and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression/unacceptable toxicity.
Drug: Placebo
Intravenously every 2 weeks in the Concurrent and Maintenance Phases and every 3 weeks in the Monotherapy Phase.
Drug: temozolomide
75 mg/m2 once daily for 6 weeks, followed by 150-200 mg/m2 once daily on days 1-5 of each 6 x 4 week cycle.
Radiation: Radiation therapy
30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • newly diagnosed glioblastoma;
  • World Health Organization (WHO) performance status <=2;
  • stable or decreasing corticosteroid dose within 5 days prior to randomization.

Exclusion Criteria:

  • evidence of recent hemorrhage or postoperative magnetic resonance imaging (MRI) of brain;
  • any prior chemotherapy or immunotherapy for glioblastomas and low grade astrocytomas;
  • any prior radiotherapy to brain;
  • clinically significant cardiovascular disease;
  • history of >=grade 2 hemoptysis within 1 month prior to randomization;
  • previous centralized screening for Methylguanine-DNA methyltransferase (MGMT) status for enrollment into a clinical trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00943826

  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States, 35294
United States, California
Los Angeles, California, United States, 90095
United States, Colorado
Aurora, Colorado, United States, 80045
United States, Florida
Tampa, Florida, United States, 33612-9497
United States, Illinois
Evanston, Illinois, United States, 60201
United States, Michigan
Detroit, Michigan, United States, 48202
United States, North Carolina
Charlottesville, North Carolina, United States, 22903
United States, Ohio
Cincinnati, Ohio, United States, 45220
United States, Tennessee
Nashville, Tennessee, United States, 37203
Australia
Nedlands, Australia, 6009
North Adelaide, Australia, 5006
Parkville, Australia, 3052
Randwick, Australia, 2031
St Leonards, Australia, 2065
St. Leonards, Australia, 2065
Woolloongabba, Australia, 4102
Belgium
Bruxelles, Belgium, 1200
Bruxelles, Belgium, 1070
Edegem, Belgium, 2650
Gent, Belgium, 9000
Liège, Belgium, 4000
Roeselare, Belgium, 8800
Canada, Alberta
Calgary, Alberta, Canada, T2N 4N2
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9
Canada, Ontario
Hamilton, Ontario, Canada, L8V 5C2
Kingston, Ontario, Canada, K7L 5P9
London, Ontario, Canada, N6A 5A5
Ottawa, Ontario, Canada, K1H 1C4
Toronto, Ontario, Canada, M4N 3M5
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Montreal, Quebec, Canada, H2L 4M1
Montreal, Quebec, Canada, H3A 2B4
Quebec City, Quebec, Canada, G1R 2J6
Canada, Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N 4H4
Denmark
Aalborg, Denmark, 9000
Copenhagen, Denmark, 2100
Odense, Denmark, 5000
France
Bobigny, France, 93009
Bordeaux, France, 33076
Bordeaux, France, 33075
Bron, France, 69677
Clermont Ferrand, France, 63011
Clichy, France, 92118
Dijon, France, 21079
Marseille, France, 13385
Montpellier, France, 34298
Nancy, France, 54000
Paris, France, 75651
Germany
Dresden, Germany, 01307
Giessen, Germany, 35385
Hamburg, Germany, 20246
Heidelberg, Germany, 69120
Mainz, Germany, 55131
Muenchen, Germany, 81377
Velen, Germany, 46342
Greece
Heraklion, Greece, 71110
Larissa, Greece, 41110
Thessaloniki, Greece, 56429
Hong Kong
Hong Kong, Hong Kong
Hungary
Budapest, Hungary, 1062
Miskolc, Hungary, 3526
Pecs, Hungary, 7624
Szeged, Hungary, 6725
Israel
Haifa, Israel, 31096
Jerusalem, Israel, 91120
Petach Tikva, Israel, 49100
Tel Hashomer, Israel, 52621
Italy
Bologna, Italy, 40139
Forli, Italy, 47023
Milano, Italy, 20133
Terni, Italy, 05100
Torino, Italy, 10126
Treviso, Italy, 31100
Japan
Hiroshima, Japan, 734-8551
Ibaraki, Japan, 305-8576
Kumamoto, Japan, 860-8556
Osaka, Japan, 530-8480
Saitama, Japan, 350-1298
Tokyo, Japan, 104-0045
Tokyo, Japan, 181-8611
Tokyo, Japan, 113-8677
Korea, Republic of
Busan, Korea, Republic of, 602-739
Daegu, Korea, Republic of, 700-721
Goyang-si, Korea, Republic of, 410-769
Hwasun, Korea, Republic of, 519-809
Seoul, Korea, Republic of, 135-170
Seoul, Korea, Republic of, 120-752
Seoul, Korea, Republic of, 110-744
Seoul, Korea, Republic of, 138-736
Netherlands
Amsterdam, Netherlands, 1081 HV
Eindhoven, Netherlands, 5623 EJ
Utrecht, Netherlands, 3584 CX
New Zealand
Auckland, New Zealand, 100
Christchurch, New Zealand
Hamilton, New Zealand
Poland
Bialystok, Poland, 15-027
Bydgoszcz, Poland, 85-796
Lublin, Poland, 20-954
Portugal
Coimbra, Portugal, 3000-075
Lisboa, Portugal, 1099-023
Lisboa, Portugal, 1649-035
Porto, Portugal, 4200-319
Romania
Bucharest, Romania, 022328
Cluj-napoca, Romania, 400015
Targu Mures, Romania, 540142
Russian Federation
Moscow, Russian Federation, 115478
Moscow, Russian Federation, 125047
Moscow, Russian Federation, 105229
St. Petersburg, Russian Federation, 194175
Spain
Barcelona, Spain, 08916
Barcelona, Spain, 08907
Barcelona, Spain, 08036
Madrid, Spain, 28046
Madrid, Spain, 28034
Malaga, Spain, 29010
Valencia, Spain, 46010
Sweden
Göteborg, Sweden, 413 45
Lund, Sweden, 22185
Umea, Sweden, 901 85
Uppsala, Sweden, 751 85
Switzerland
Geneve, Switzerland, 1211
United Kingdom
Birmingham, United Kingdom, B15 2TT
Bristol, United Kingdom, BS1 3NU
London, United Kingdom, SW3 6JJ
Merseyside, United Kingdom, CH63 45Y
Newcastle Upon Tyne, United Kingdom, NE7 7DN
Nottingham, United Kingdom, NG5 1PB
Romford, United Kingdom, RM7 0AG
Sheffield, United Kingdom, S1O 2SJ
Sutton, United Kingdom, SM2 5PT
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided by Hoffmann-La Roche

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00943826     History of Changes
Other Study ID Numbers: BO21990, 2008-006146-26
Study First Received: July 17, 2009
Results First Received: March 29, 2013
Last Updated: September 6, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Dacarbazine
Bevacizumab
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors

ClinicalTrials.gov processed this record on August 20, 2014